Biomea Fusion EBITDA 2020-2025 | BMEA

Prices Financials Revenue & Profit Assets & Liabilities Margins Price Ratios Other Ratios Other Metrics

Revenue Gross Profit Operating Income EBITDA Net Income Shares Outstanding

Biomea Fusion ebitda from 2020 to 2025. Ebitda can be defined as earnings before interest, taxes, depreciation and amortization.

Prices Financials Revenue & Profit Assets & Liabilities Margins Price Ratios Other Ratios Other Metrics

Revenue Gross Profit Operating Income EBITDA Net Income Shares Outstanding

Biomea Fusion ebitda from 2020 to 2025. Ebitda can be defined as earnings before interest, taxes, depreciation and amortization.

Related Stocks
Company Name	Market Cap
AstraZeneca (AZN)	$247.8B
Amgen (AMGN)	$154.9B
Gilead Sciences (GILD)	$140.2B
Vertex Pharmaceuticals (VRTX)	$100.3B
Bristol Myers Squibb (BMY)	$96B
GSK (GSK)	$80.8B
CSL (CSLLY)	$67.1B
Regeneron Pharmaceuticals (REGN)	$61.5B
Alnylam Pharmaceuticals (ALNY)	$58.5B
Argenex SE (ARGX)	$43.6B
Insmed (INSM)	$28.8B
BioNTech SE (BNTX)	$24B
Royalty Pharma (RPRX)	$21B
Biogen (BIIB)	$19.4B
Incyte (INCY)	$16.5B
Genmab (GNMSF)	$16.5B
Genmab (GMAB)	$16B
Illumina (ILMN)	$15.4B
Ascendis Pharma (ASND)	$11.9B
BioMarin Pharmaceutical (BMRN)	$11.2B
Swedish Orphan Biovitrum (BIOVF)	$10.9B
QIAGEN (QGEN)	$10.3B
Exelixis (EXEL)	$10.1B
Moderna (MRNA)	$9.4B
Verona Pharma American Depositary Share (VRNA)	$9.2B
Exact Sciences (EXAS)	$9B
Bio-Techne Corp (TECH)	$8.6B
Halozyme Therapeutics (HALO)	$8.6B
Guardant Health (GH)	$8.4B
Blueprint Medicines (BPMC)	$8.3B